CA2979527A1 - Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease - Google Patents

Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease

Info

Publication number
CA2979527A1
CA2979527A1 CA2979527A CA2979527A CA2979527A1 CA 2979527 A1 CA2979527 A1 CA 2979527A1 CA 2979527 A CA2979527 A CA 2979527A CA 2979527 A CA2979527 A CA 2979527A CA 2979527 A1 CA2979527 A1 CA 2979527A1
Authority
CA
Canada
Prior art keywords
alkyl
alkenyl
alkynyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2979527A
Other languages
English (en)
French (fr)
Inventor
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Longwu Qi
Yingcai Wang
Kevin Yu Wang
Ning Zou
Albert E. FELTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CA2979527A1 publication Critical patent/CA2979527A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA2979527A 2015-03-13 2015-03-13 Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease Pending CA2979527A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/020397 WO2016148674A1 (en) 2015-03-13 2015-03-13 Conjugates for treating diseases

Publications (1)

Publication Number Publication Date
CA2979527A1 true CA2979527A1 (en) 2016-09-22

Family

ID=56920017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979527A Pending CA2979527A1 (en) 2015-03-13 2015-03-13 Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease

Country Status (6)

Country Link
US (2) US10624972B2 (enExample)
EP (1) EP3268046A4 (enExample)
JP (1) JP6676650B2 (enExample)
CN (1) CN107847609A (enExample)
CA (1) CA2979527A1 (enExample)
WO (1) WO2016148674A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968837A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
WO2017172930A1 (en) * 2016-03-29 2017-10-05 Endocyte, Inc. Pbd conjugates for treating diseases
US20190216935A1 (en) * 2016-05-25 2019-07-18 Purdue Research Foundation Method of treating cancer by targeting myeloid-derived suppressor cells
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR20210086557A (ko) 2019-12-31 2021-07-08 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 유도체 및 이의 리간드-링커 접합체

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
AU634314B2 (en) 1989-11-13 1993-02-18 Green Cross Corporation, The Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ES2171392T3 (es) 1990-08-29 2002-09-16 Ct Hospitalier Regional De Nan Poliligandos de proteina unidos a un nucleo de proteina estable.
AUPN449295A0 (en) * 1995-07-28 1995-08-24 Inner And Eastern Health Care Network, The Radioprotectors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
EP1206285A2 (en) * 1999-08-09 2002-05-22 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
CN101287500A (zh) * 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
BRPI0615354A2 (pt) * 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
CA2676297A1 (en) 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibitors of hepatitis c ns3 protease
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN102215844A (zh) 2008-09-17 2011-10-12 恩多塞特公司 抗叶酸剂的叶酸受体结合轭合物
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
US20130065841A1 (en) 2010-05-19 2013-03-14 Endocyte, Inc. Process for a folate-targeted agent
IL279304B (en) 2011-02-15 2022-07-01 Immunogen Inc Method for producing an indolinobenzodiazepine
CA2807712A1 (en) * 2012-03-01 2013-09-01 Purdue Research Foundation Methods for treating cancer
HK1212618A1 (zh) * 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
KR102354613B1 (ko) * 2012-11-15 2022-01-21 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
EP2922818B1 (en) * 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN107001479B (zh) 2014-09-12 2021-09-28 基因泰克公司 抗her2抗体和免疫缀合物
CA2968837A1 (en) 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
JP6676650B2 (ja) 2015-03-13 2020-04-08 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート
WO2017172930A1 (en) 2016-03-29 2017-10-05 Endocyte, Inc. Pbd conjugates for treating diseases

Also Published As

Publication number Publication date
CN107847609A (zh) 2018-03-27
US20180228914A1 (en) 2018-08-16
JP6676650B2 (ja) 2020-04-08
JP2018509424A (ja) 2018-04-05
US10624972B2 (en) 2020-04-21
WO2016148674A1 (en) 2016-09-22
EP3268046A4 (en) 2018-11-21
EP3268046A1 (en) 2018-01-17
US20200289659A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
TWI440641B (zh) 蛋白酶體抑制劑
AU2023203341A1 (en) Silicon based drug conjugates and methods of using same
US20200289659A1 (en) Conjugates for treating diseases
CA3026651A1 (en) Silanol based therapeutic payloads
CZ20023330A3 (cs) Konjugáty kamptotecinu a polyglutamové kyseliny a způsoby přípravy
WO2010045598A2 (en) Psma binding ligand-linker conjugates and methods for using
US11484600B2 (en) Intermediate drug with synergistic anticancer activity and polyethylene glycol-coupled synergistic anticancer drug, and preparation method therefor and use thereof
US20200323991A1 (en) Pbd conjugates for treating diseases
WO2016168471A1 (en) Dual disulfide drug conjugates
US10500286B2 (en) CCK2R-drug conjugates
KR20030096226A (ko) 개선된 세포간 전달을 보이는 디옥소란 동족체
WO2016089879A1 (en) Conjugates of garftase inhibitors
WO2021051720A1 (zh) 一类抗人egfr抗体药物偶联物及其制备方法与应用
CA2792598C (en) Improved cysteine-based prodrugs useful in the treatment of schizophrenia
JP2021006550A (ja) 炎症の治療のための抗葉酸剤結合体
US20160303251A1 (en) Conjugates of garftase inhibitors
CN104587487B (zh) 一种应用于靶向给药系统的新的支链连接体
US20180125992A1 (en) Drug delivery conjugates of tertiary amine containing drugs
JP2014509613A (ja) Ｄ−イソグルタミル−［ｄ／ｌ］−トリプトファンのプロドラッグ
JP2020117509A (ja) 疾患を処置するためのコンジュゲート
WO2015069766A1 (en) Dupa-indenoisoquinoline conjugates
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
TW202325273A (zh) 靶向fap之中子捕獲劑及與其相關之用途及調配物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311

EEER Examination request

Effective date: 20200311